Stamm Biotech
Private Company
Total funding raised: $5.5M
Overview
Stamm Biotech is a private, pre-revenue biotech platform company focused on transforming biomanufacturing for biologics and cell therapies through automation, continuous processing, and artificial intelligence. Its core offerings include a proprietary High-throughput Bioprocessor for production, end-to-end bioengineering services for cell line development, and a Bio AI platform called MoNA for predictive cell modeling. By integrating engineering and data science, Stamm aims to make bioprocesses more scalable, efficient, and sustainable, primarily serving the research and development needs of partners in the life sciences industry.
Technology Platform
Integrated platform combining a High-throughput Bioprocessor for automated continuous biomanufacturing, bioengineering services for cell line development, and the MoNA AI platform for predictive cell modeling using multi-omic data.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Stamm competes in the bioprocessing equipment and services market against large conglomerates like Sartorius, Thermo Fisher, and Danaher, as well as other innovators in continuous processing and AI for biomanufacturing. Its differentiation lies in the tight integration of a proprietary continuous bioprocessor with a generative AI platform designed specifically for cell behavior prediction and process optimization.